Auricular Vagal Nerve Stimulation for Hypermobile Ehlers-Danlos Syndrome

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age10-18
SponsorMedical College of Wisconsin

About this trial

Hypermobile Ehlers-Danlos Syndrome (hEDS) is a connective tissue disorder characterized by hyperextensible skin, joint hypermobility and additional connective tissue manifestations. For unclear reasons, hEDS is associated with many gastrointestinal (GI) and autonomic nervous system (ANS) complaints such as postural orthostatic tachycardia syndrome (POTS). This study will address the clinical relationship between hEDS/Hypermobile Spectrum Disorders and autonomic regulation and see if there is a benefit of two forms of non-invasive vagal nerve stimulation therapies to reduce GI symptoms in hEDS and POTS. The study will also investigate plausible effects of these nerve stimulation therapies on gastric function and autonomic signaling.

Eligibility criteria

Qualifiers

Children aged 10-18 years old

Children with functional upper GI complaints and clinical suspicion for hEDS or HSD as well as a Beighton score of at least 4/9

Children with functional upper GI complaints and clinical suspicion for ANS dysfunction

De-identified data from our prior studies (IRB #689519 and IRB #1064187) of patients with functional GI disorders who do NOT meet criteria for hEDS will be used as a comparison group

Disqualifiers

Medically complex children or those who take a medication or suffer from a disease that can explain symptoms will be excluded from participation in the study.

Adult subjects, children or their parents who have significant developmental delay (will be excluded due to difficulties in accurately completing the questionnaires and assessing symptoms)

Patients with findings of organic disease such as peptic ulcer disease, H.pylori gastritis, celiac disease, inflammatory bowel disease, allergic disorders, metabolic disorder or any other chronic condition or medication that may cause chronic GI symptoms will be excluded from the study.

Patients who are treated with a new drug affecting the central nervous system in the two weeks prior to enrollment will also be excluded.

Trial design

Treatments tested in this trial

  • Percutaneous vagal nerve stimulation (pVNS) device
  • Acoustic vagal nerve stimulation (aVNS) treatment

Treatment groups

90 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Medical College of Wisconsin

Lead sponsor

University College, London

Collaborator

Indiana University

Collaborator